Who
Joshua M. Eizen
Officer
Company insider
Files Form 4 as: Chief Legal Officer, AN2 Therapeutics.
In numbers
- Trades disclosed
- 30
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $116K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 14 Oct 2022
- Last trade
- 8 Jul 2026
- Last filed
- 10 Jul 2026
Companies traded
Activity over time
1 Dec 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Jul 2026filed 10 Jul 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Sold | $25K5,945 at $4.17 | filing |
| 8 Jul 2026filed 10 Jul 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Sold | $25K5,945 at $4.17 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —92,000 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —92,000 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,150 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —92,000 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —92,000 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,150 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —50,150 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —50,150 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 6 Jan 2026filed 7 Jan 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Sold | $7,0146,931 at $1.01 | filing |
| 6 Jan 2026filed 7 Jan 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Sold | $7,0006,931 at $1.01 | filing |
| 5 Jan 2026filed 7 Jan 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Sold | $18K17,923 at $1.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Sold | $18K17,923 at $1.00 | filing |
| 4 Nov 2025filed 6 Nov 2025 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Sold | $3,2142,819 at $1.14 | filing |
| 26 Feb 2025filed 28 Feb 2025 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —117,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.